Pediatr Gastroenterol Hepatol Nutr.  2020 Jan;23(1):63-71. 10.5223/pghn.2020.23.1.63.

Polymorphism in Macrophage Migration Inhibitory Factor -173GC in Pediatric Patients with Autoimmune Hepatitis

• Alsayed MA
• Elbeah SM
• El-Desoky
• Elziny SM
• Megahed A

• KMID: 2467894
• DOI: http://doi.org/10.5223/pghn.2020.23.1.63

Abstract

PURPOSE
Autoimmune hepatitis (AIH) is a chronic disease that may lead to cirrhosis. The immunopathogenesis of AIH is not fully understood and it mainly involves T-cell mediated mechanism. Macrophage migration inhibitory factor (MIF) is a pro-inflammatory cytokine that promotes T cell response and its polymorphism may serve as a severity marker of AIH. No previous study has considered investigating MIF polymorphism in children with AIH.
METHODS
Forty-two children with definite diagnosis of AIH were enrolled along with 100 age and sex matched controls. All participants were tested for polymorphism at -173GC (rs755622) of MIF gene. All patients received the standard protocol of steroid plus azathioprine to achieve remission. Liver biopsy was performed at time of diagnosis for all patients and only 18 of them underwent a second biopsy after treatment.
RESULTS
No statistically significant differences in the frequency of the genotypes GG and GC or in allele distribution were found in both patient and control groups (p=0.590, 0.640 respectively). Initial alanine aminotransferase (ALT) levels at the time of presentation was significantly higher in the GC group than GG group (p=0.020). GC genotype significantly correlated with disease relapse (r=0.41, p=0.007). Regression of necroinflammation and the fibrosis score in the second liver biopsy was statistically significant in the GG group (p < 0.0001, p=0.010 respectively).
CONCLUSION
MIF -173GC polymorphism is associated with clinically significant markers of pediatric AIH, including increased initial serum ALT levels, may help predict necroinflammatory/fibrosis regression effectively, following immunosuppressive treatment.

Keyword

Autoimmune hepatitis; Children; Macrophage migration inhibitory factor; −173 GC polymorphism

MeSH Terms

Alanine Transaminase
Alleles
Azathioprine
Biopsy
Child
Chronic Disease
Diagnosis
Fibrosis
Genotype
Hepatitis, Autoimmune*
Humans
Liver
Macrophages*
Recurrence
T-Lymphocytes
Alanine Transaminase
Azathioprine

Figure

• 

  Fig. 1 Gel electrophoresis of polymerase chain reaction product. Lane 1 contains 50 bp DNA ladder. Lanes 4, 5, 6, 7, and 10 contain two bands of 268 and 97 bp that are indicators of GG genotype, lanes 2, 3, 8, and 9 contain four bands (268, 206, 97, and 62 bp) that represent GC genotype, while 3 bands (206, 97, and 62 bp) of CC genotype are absent.

• 

  Fig. 2 Error bar representing the mean steroid dose in different genotypic patient groups.CI: confidence interval.

Reference

1. Maggiore G, Veber F, Bernard O, Hadchouel M, Homberg JC, Alvarez F, et al. Autoimmune hepatitis associated with anti-actin antibodies in children and adolescents. J Pediatr Gastroenterol Nutr. 1993; 17:376–381. PMID: 8145091.

2. Mieli-Vergani G, Heller S, Jara P, Vergani D, Chang MH, Fujisawa T, et al. Autoimmune hepatitis. J Pediatr Gastroenterol Nutr. 2009; 49:158–164. PMID: 19561543.

3. Gregorio GV, Portmann B, Reid F, Donaldson PT, Doherty DG, McCartney M, et al. Autoimmune hepatitis in childhood: a 20-year experience. Hepatology. 1997; 25:541–547. PMID: 9049195.

4. Mieli-Vergani G, Vergani D. Autoimmune paediatric liver disease. World J Gastroenterol. 2008; 14:3360–3367. PMID: 18528933.

5. Czaja AJ, Menon KV, Carpenter HA. Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis. Hepatology. 2002; 35:890–897. PMID: 11915036.

6. Czaja AJ. Difficult treatment decisions in autoimmune hepatitis. World J Gastroenterol. 2010; 16:934–947. PMID: 20180231.

7. de Boer YS, van Gerven NM, Zwiers A, Verwer BJ, van Hoek B, van Erpecum KJ, et al. Genome-wide association study identifies variants associated with autoimmune hepatitis type 1. Gastroenterology. 2014; 147:443–52.e5. PMID: 24768677.

8. Czaja AJ, Manns MP. Advances in the diagnosis, pathogenesis, and management of autoimmune hepatitis. Gastroenterology. 2010; 139:58–72.e4. PMID: 20451521.

9. Vergani D, Mieli-Vergani G. Aetiopathogenesis of autoimmune hepatitis. World J Gastroenterol. 2008; 14:3306–3312. PMID: 18528928.

10. Calandra T, Bernhagen J, Metz CN, Spiegel LA, Bacher M, Donnelly T, et al. MIF as a glucocorticoid-induced modulator of cytokine production. Nature. 1995; 377:68–71. PMID: 7659164.

11. Bucala R. MIF, MIF alleles, and prospects for therapeutic intervention in autoimmunity. J Clin Immunol. 2013; 33(Suppl 1):S72–S78. PMID: 22968741.

12. Assis DN, Leng L, Du X, Zhang CK, Grieb G, Merk M, et al. The role of macrophage migration inhibitory factor in autoimmune liver disease. Hepatology. 2014; 59:580–591. PMID: 23913513.

13. Assis DN, Takahashi H, Leng L, Zeniya M, Boyer JL, Bucala R. A macrophage migration inhibitory factor polymorphism is associated with autoimmune hepatitis severity in US and Japanese patients. Dig Dis Sci. 2016; 61:3506–3512. PMID: 27696094.

14. Hennes EM, Zeniya M, Czaja AJ, Parés A, Dalekos GN, Krawitt EL, et al. International Autoimmune Hepatitis Group. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008; 48:169–176. PMID: 18537184.

15. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995; 22:696–699. PMID: 7560864.

16. Roberts S, Leng L, Soroka CJ, Boyer JL, Bucala R, Assis DN. Macrophage migration inhibitory factor (MIF) modulates T-cell proliferation and hepatic inflammation in a model of autoimmune liver disease. J Hepatol. 2017; 66:S363–4.

17. Sreih A, Ezzeddine R, Leng L, LaChance A, Yu G, Mizue Y, et al. Dual effect of the macrophage migration inhibitory factor gene on the development and severity of human systemic lupus erythematosus. Arthritis Rheum. 2011; 63:3942–3951. PMID: 22127710.

18. Foote A, Briganti EM, Kipen Y, Santos L, Leech M, Morand EF. Macrophage migration inhibitory factor in systemic lupus erythematosus. J Rheumatol. 2004; 31:268–273. PMID: 14760795.

19. Llamas-Covarrubias MA, Valle Y, Bucala R, Navarro-Hernández RE, Palafox-Sánchez CA, Padilla-Gutiérrez JR, et al. Macrophage migration inhibitory factor (MIF): genetic evidence for participation in early onset and early stage rheumatoid arthritis. Cytokine. 2013; 61:759–765. PMID: 23402792.

20. Zhang H, Ma L, Dong LQ, Shu C, Xu JL. Association of the macrophage migration inhibitory factor gene--173G/C polymorphism with inflammatory bowel disease: a meta-analysis of 4296 subjects. Gene. 2013; 526:228–231. PMID: 23707797.

21. Berdeli A, Mir S, Ozkayin N, Serdaroglu E, Tabel Y, Cura A. Association of macrophage migration inhibitory factor -173C allele polymorphism with steroid resistance in children with nephrotic syndrome. Pediatr Nephrol. 2005; 20:1566–1571. PMID: 16133063.

22. Arikan C, Berdeli A, Ozgenc F, Tumgor G, Yagci RV, Aydogdu S. Positive association of macrophage migration inhibitory factor gene-173G/C polymorphism with biliary atresia. J Pediatr Gastroenterol Nutr. 2006; 42:77–82. PMID: 16385258.

23. Sadek KH, Ezzat S, Abdel-Aziz SA, Alaraby H, Mosbeh A, Abdel-Rahman MH. Macrophage migration inhibitory factor (MIF) gene promotor polymorphism is associated with increased fibrosis in biliary atresia patients, but not with disease susceptibility. Ann Hum Genet. 2017; 81:177–183. PMID: 28657145.

24. Akyildiz M, Gunsar F, Nart D, Sahin O, Yilmaz F, Akay S, et al. Macrophage migration inhibitory factor expression and MIF gene -173 G/C polymorphism in nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol. 2010; 22:192–198. PMID: 19829123.

25. Moudi B, Heidari Z, Mahmoudzadeh-Sagheb H, Hashemi M. Gene polymorphisms of macrophage migration inhibitory factor affect susceptibility to chronic hepatitis B virus infection in an Iranian cohort. Microbiol Immunol. 2016; 60:390–396. PMID: 27079941.

26. Zhang HY, Nanji AA, Luk JM, Huang XR, Lo CM, Chen YX, et al. Macrophage migration inhibitory factor expression correlates with inflammatory changes in human chronic hepatitis B infection. Liver Int. 2005; 25:571–579. PMID: 15910495.

27. Zhang K, Pan X, Shu X, Cao H, Chen L, Zou Y, et al. Relationship between MIF-173 G/C polymorphism and susceptibility to chronic hepatitis B and HBV-induced liver cirrhosis. Cell Immunol. 2013; 282:113–116. PMID: 23770720.

28. Bahgat DMR, Saïd S, Gheith RE. Non-significant influence of macrophage migration inhibitory factor (MIF) promoter gene polymorphisms on the risk or activity of Egyptian Behçet’s disease patients: potential role of MIF+254T/C in posterior uveitis. Egypt Rheumatol. 2017; 39:115–120.

29. El-Edel RH, El-Din RIN, El-Zayat RS, El-Bagoury HAM. Association of macrophage migration inhibitory factor -173G/C polymorphism with dilated cardiomyopathy in children. Menoufia Med J. 2018; 31:306–310.

30. Radstake TR, Sweep FC, Welsing P, Franke B, Vermeulen SH, Geurts-Moespot A, et al. Correlation of rheumatoid arthritis severity with the genetic functional variants and circulating levels of macrophage migration inhibitory factor. Arthritis Rheum. 2005; 52:3020–3029. PMID: 16200611.